alanine has been researched along with Abnormal Movements in 5 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain." | 8.12 | Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. ( Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022) |
| "Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain." | 4.12 | Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. ( Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022) |
| "Safinamide is a unique treatment modulating both dopaminergic and glutamatergic systems." | 2.94 | Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. ( Bonizzoni, E; Cattaneo, C; Jost, WH, 2020) |
| "Safinamide is a novel α-aminoamide with dopaminergic and non-dopaminergic properties developed as adjunctive therapy for patients with PD." | 2.80 | Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. ( Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Larson, D | 1 |
| Simuni, T | 1 |
| Rizzone, MG | 1 |
| Mancini, F | 1 |
| Artusi, CA | 1 |
| Balestrino, R | 1 |
| Bonvegna, S | 1 |
| Fabbri, M | 1 |
| Imbalzano, G | 1 |
| Montanaro, E | 1 |
| Romagnolo, A | 1 |
| Zibetti, M | 1 |
| Lopiano, L | 1 |
| Hattori, N | 1 |
| Kamei, T | 1 |
| Ishida, T | 1 |
| Suzuki, I | 1 |
| Nomoto, M | 1 |
| Tsuboi, Y | 1 |
| Cattaneo, C | 2 |
| Jost, WH | 1 |
| Bonizzoni, E | 2 |
| Ferla, RL | 1 |
| Sardina, M | 1 |
1 review available for alanine and Abnormal Movements
| Article | Year |
|---|---|
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progr | 2022 |
3 trials available for alanine and Abnormal Movements
| Article | Year |
|---|---|
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; | 2020 |
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2015 |
1 other study available for alanine and Abnormal Movements
| Article | Year |
|---|---|
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Diseas | 2022 |